Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Kohei ShigetaMeenal DattaTai HatoShuji KitaharaIvy X ChenAya MatsuiHiroto KikuchiEmilie MamessierShuichi AokiRakesh R RamjiawanHiroki OchiaiNabeel BardeesyPeigen HuangMark CobboldAndrew X ZhuRakesh K JainDan G DudaPublished in: Hepatology (Baltimore, Md.) (2019)
We show that dual anti-PD-1/VEGFR-2 therapy has a durable vessel fortification effect in HCC and can overcome treatment resistance to either treatment alone and increase overall survival in both anti-PD-1 therapy-resistant and anti-PD-1 therapy-responsive HCC models.